Sign in

SCNI on Nasdaq

Scinai Immunotherapeutics Ltd.

Scinai Immunotherapeutics Ltd. is a biological products company that raised $3 million in 2023 (SEC Form D).1 Its shares trade on Nasdaq under the symbol SCNI.1

Price unavailable

Last updated Oct 21, 2026.

Overview

$1.3MRevenue, fiscal 20252
-$8.3MNet income, fiscal 20252

Compare with Inhibrx Biosciences, Inc., SAB Biotherapeutics, Inc. or Cidara Therapeutics, or pick any stock.

  • TickerSCNI on Nasdaq1
  • IndustryBiological Products, (No Diagnostic Substances)1
  • HeadquartersL31
  • Incorporated inIsrael3
  • Business addressJerusalem Biopark, 2Nd Floor, Hadassah Ein Kerem Campus, Jerusalem, L3 000003
  • Filer categoryNon-accelerated filer3
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

Funds for a Modern Economy (FENG) program for our wholly owned Polish subsidiary or securing $3 million to fund the development of PC111.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-202.3%Gross margin2
-575.3%Operating margin2
-633.6%Net margin2
99.2%Revenue growth, 20252
-102.5%Return on equity2
-$6.1MFree cash flow2

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue45¢$4.0M
  • Research and development27¢$2.4M
  • Selling, general and admin28¢$2.5M

Out of $1.3M in revenue.2 The company lost money this year.

Financial statements

Revenue2$1.3M in 2025+99% since 2024
0$500.0K$1.0M$1.5M2024: $658.0K$658.0K20242025: $1.3M$1.3M2025+99%
Gross profit2-$2.7M in 2025+357% since 2024
-$3.0M-$2.0M-$1.0M02024: -$580.0K-$580.0K20242025: -$2.7M-$2.7M2025+357%
Operating income562-$7.5M in 2025−31% since 2021
-$15.0M-$10.0M-$5.0M02021: -$10.9M-$10.9M20212022: -$11.1M-$11.1M2022+2%2023: -$9.7M-$9.7M2023−12%2024: -$8.6M-$8.6M2024−11%2025: -$7.5M-$7.5M2025−13%
Net income7862-$8.3M in 2025+499% since 2020
-$10.0M-$5.0M0$5.0M2020: -$1.4M-$1.4M20202021: -$8.2M-$8.2M2021+492%2022: -$5.8M-$5.8M2022−29%2023: -$6.5M-$6.5M2023+12%2024: $4.8M$4.8M20242025: -$8.3M-$8.3M2025

Every line of the income statement as filed: the last 3 fiscal years, latest first.2

Period ending2025-12-312024-12-312023-12-31
Revenues$1.3M$658.0K
Cost of revenues-$4.0M-$1.2M
Gross profit (loss)-$2.7M-$580.0K
Research and development expenses, net-$2.4M-$5.5M-$5.2M
Marketing, general and administrative expenses-$2.5M-$2.5M-$4.5M
Other income$9.0K
Total operating expenses-$4.9M-$8.1M-$9.7M
Total operating loss-$7.5M-$8.6M-$9.7M
Gain on troubled debt restructuring$250.0K$14.8M
Financial income (expenses) net,-$765.0K-$1.3M$3.2M
Net Income (Loss)-$8.3M$4.8M-$6.5M
Net loss (Income) per ordinary share attributable to shareholders, basic (in Dollars per share)$0.00
Net loss (Income) per ordinary share attributable to shareholders, diluted (in Dollars per share)$0.00
Weighted average number of shares used in computing net loss (income) per share attributable to ordinary shareholders, basic (in Shares)9.3B shares3.2B shares1.6B shares

Compare Scinai Immunotherapeutics Ltd. with another company

Corporate structure

Scinai Immunotherapeutics Ltd. sits at the top of its group. 1 entity on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Scinai Immunotherapeutics Ltd.

  • LCK JNK 1 LLC Filed SCHEDULE 13G/A on Scinai Immunotherapeutics Ltd., latest Jul 9, 2026 (3 filings since Feb 24, 2025)
  • Daniel E. Stone Filed SCHEDULE 13G/A on Scinai Immunotherapeutics Ltd., latest Jul 1, 2026 (9 filings since Oct 6, 2022)
  • YA II PN, Ltd. Filed SCHEDULE 13G on Scinai Immunotherapeutics Ltd., latest Mar 26, 2025
  • SABBY MANAGEMENT, LLC Filed SCHEDULE 13G on Scinai Immunotherapeutics Ltd., latest Jan 3, 2025 (3 filings since Jan 4, 2023)
  • ARMISTICE CAPITAL, LLC Filed SC 13G/A on Scinai Immunotherapeutics Ltd., latest Nov 14, 2024 (2 filings since Feb 14, 2024)
  • Marius Nacht Filed SC 13D/A on Scinai Immunotherapeutics Ltd., latest Dec 27, 2022 (2 filings since Jan 11, 2022)
  • Scinai Immunotherapeutics Ltd. L3

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Scinai Immunotherapeutics Ltd. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$13.7M2 Dec 31, 2025$13.6M2 Dec 31, 2024+0.2%
Accumulated depreciation$5.9M2 Dec 31, 2025$4.5M2 Dec 31, 2024+31.9%
Property and equipment, net$7.8M2 Dec 31, 2025$9.2M2 Dec 31, 2024−15.2%
Operating-lease assets (leased space)$1.8M2 Dec 31, 2025$1.9M2 Dec 31, 2024−4.8%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$1.7M2 Dec 31, 2025$2.0M2 Dec 31, 2024−15.4%

Leadership

Who has led Scinai Immunotherapeutics Ltd., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Amir Reichman2023–now

Chief financial officer

  1. Uri Ben-Or2023

Chief operating officer

  1. Elad Mark2023–now
2025
Board members and other officers (11)

Former names

  • BiondVax Pharmaceuticals Ltd.Nov 13, 2014 to Aug 28, 20233

Timeline

  1. Jun 8, 20238-K Entered a material agreement23
  2. May 11, 20238-K Executive or director change24
  3. May 4, 20238-K Regulation FD disclosure25
  4. May 4, 20238-K Listing notice or transfer26
  5. Jan 3, 2023New chief executive Amir Reichman becomes CEO10

Calendar

Coming up

  1. Nov 23, 2026Reports results for the quarter ending Sep/202627

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

242 filings to the SEC since October 2021: 5 annual reports, 1 quarterly reports, 4 major events, 26 insider forms, 20 large holders, 2 private raises, 184 other. The latest 20:

  1. Oct 15, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  2. Oct 13, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  3. Oct 5, 2026EFFECT EDGAR
  4. Sep 24, 2026F-1 REGISTRATION STATEMENT EDGAR
  5. Sep 21, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  6. Sep 8, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  7. Aug 28, 2026EFFECT EDGAR
  8. Aug 27, 2026POS AM POST-EFFECTIVE AMENDMENT NO. 1 TO FORM F-1 EDGAR
  9. Aug 26, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  10. Aug 19, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  11. Jul 9, 2026SCHEDULE 13G/A EDGAR
  12. Jul 1, 2026SCHEDULE 13G/A EDGAR
  13. Jun 18, 20264 EDGAR
  14. Jun 18, 20264 EDGAR
  15. Jun 17, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  16. Jun 15, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  17. Jun 8, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  18. May 19, 2026EFFECT EDGAR
  19. May 19, 2026424B3 PROSPECTUS EDGAR
  20. May 15, 2026CORRESP EDGAR

The 242 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Dec 29, 2023Raised $1.7 million in a private offering of equity Form D: 4 investors so far Form D
  2. Sep 19, 2023Raised $1.3 million in a private offering of equity Form D: 1 investor so far Form D

SEC filer profile

How Scinai Immunotherapeutics Ltd. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARScinai Immunotherapeutics Ltd.1
  • CIK0001611747
  • Filer statusNon-accelerated filer not an emerging growth company; not a shell company4
  • Incorporated inL34
  • Fiscal year endsDecember 311
  • Industry code (SIC)2836 Biological Products, (No Diagnostic Substances)1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business addressJerusalem Biopark, 2Nd Floor, Hadassah Ein Kerem Campus, Jerusalem, L3 000001
  • Phone972-8-93025291
  • Shares outstanding13,872,899,584 shares as of Dec 31, 20254
  • AuditorZiv Haft, Tel-Aviv, Israel PCAOB ID 1309; no auditor attestation of internal control over financial reporting4
  • On EDGAR sinceNov 13, 20141
  • Filings492 in all: 6-K (279), CORRESP (26), 3 (20), EFFECT (19), F-1/A (13), UPLOAD (11), 20-F (10), 424B3 (10)1
    All 40 form types

    424B5 (10), 6-K/A (8), SC 13G/A (8), F-1 (7), POS AM (7), SC 13G (6), SCHEDULE 13G/A (6), F-3 (5), SC 13D/A (5), 3/A (4), 424B4 (4), 8-K (4), NT 20-F (3), S-8 (3), SCHEDULE 13G (3), 4 (2), D (2), F-3/A (2), SC 13D (2), 10-K (1), 10-Q (1), 25-NSE (1), 424A (1), 424B2 (1), 8-A12B (1), 8-A12B/A (1), CERTNAS (1), DEL AM (1), DRS (1), F-6 (1), FWP (1), NT 10-K (1)

  • Latest filingsAnnual report (20-F) Apr 1, 2026
    Quarterly report (10-Q) May 15, 2023
    Latest 8-K (8-K) Jun 8, 2023

Securities registered for trading

ClassSymbolExchange
American Depositary Shares, each representing 4,000 ordinary share, no par valueSCNINasdaq

From the cover page of the 20-F filed Apr 1, 2026 (Section 12(b) of the Exchange Act).4

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33